TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Nutritional value received by VLBW infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to Occurrence of a Bipolar Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Days Drinking Per Interval of Device Wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relapse/recurrence after ECT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumour markers assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of Subjects Achieving a CDAI Decrease of Greater Than or Equal to 10 Points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Achieving ACR20 Response Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with no treatment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Fugl-Meyer upper extremity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bladder Pain/Interstitial Cystitis Symptom Score (BPIC-SS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in refractive errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased risk of neurological impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Relapse/recovery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Health
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of clinical malaria episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in knowledge on smoking hazards
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in self-efficacy to deliver smoking cessation advices
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in bruxism events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Medically Attended RSV Confirmed LRTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of subjects alive and free of respiratory failure
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of subjects free of the need for continued renal replacement therapy (RRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Perioperative allogeneic RBC transfusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Composite rate of renal dysfunction, myocardial infarction, stroke, seizure, deep venous thrombosis, pulmonary embolism and all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Sustained Virologic Response at 24 Weeks After Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Final ridge width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Allergic disease severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Activity Score 28 (DAS28) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of successful weaning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inspiratory muscle strength (MIP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Total Sharp Score (mTSS) at Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving American College of Rheumatology 70 (ACR70) Response at Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Blood Pressure (BP) Values (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nitroglycerin consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Confirmed clinical response of serum and urine monoclonal protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical and microbiological remission of treated infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Increase in Hemoglobin (Hb) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Migraine Attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Nasal Obstruction/Congestion Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bilateral Polyp Grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of symptoms based on results of GerdQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment response and symptomatic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom relief and patient satisfaction with treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Symptom relief measured by RDQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum level of S-100B and NSE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Coordination of care among health providers and families
Endpoint domain: Resource use
Endpoint subdomain: Delivery of care
Primary endpoint: Coordination of care between health providers and families
Endpoint domain: Resource use
Endpoint subdomain: Delivery of care
Primary endpoint: Utility of follow-up planning tools
Endpoint domain: Resource use
Endpoint subdomain: Delivery of care
Primary endpoint: Discrimination of VOC bio-markers between Pancreatic Cancer and healthy population
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft versus leukemia effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Latency to analgesia onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HCC immune score (HCCIS)
Endpoint domain: Mortality/survival
Primary endpoint: All-cause hospitalization or mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Crude Adequate Clinical and Parasitological Response (ACPR) for P. Vivax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCR-adjusted Crude Adequate Clinical and Parasitological Response (ACPR) for P. Falciparum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AST and ALT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Angle change at lumbar spine segment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Dose of indigo carmine for chromoendoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Overall Arrest Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior Teeth Arrest Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posterior Arrest Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histology of Biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in % Flow Mediated Dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Relative percentage of regulatory B cells among B cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Moderate or major bleeding complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Progression-Free Survival (PFS) Hazard Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With a Vaccine Response for Anti-gE Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-glicoprotein E (gE) Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-pneumococcal Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Adverse Events at Worst CTC Grade
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Laboratory Test Toxicity Grade Shifting From Baseline
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Scoliosis Research Society - 22r (SRS-22r)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Wide Range Achievement Test Fourth Edition (WRAT-4)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants With Solicited Adverse Events (Local & Systemic Reactogenicity)
Endpoint domain: Adverse events/effects
Primary endpoint: Number and Percentage of Participants With a HAI Antibody Titer ≥1:40 (Seroprotection)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of participants developing solicited Grade 3 or 4 local reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants developing solicited Grade 3 or 4 systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants developing treatment-emergent SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Plasma Concentration (Cmax) of Asenapine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Plasma Concentration (Tmax) of Asenapine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From 0 to 12 Hours Post Dose (AUC0-12) of Asenapine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal Phase (Elimination) Half-life (t1/2) of Asenapine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of expression of intestinal localization molecules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: hamstrings peak torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: torque in 30 degrees of the knee flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak torque hamstring to quadriceps ratio (H/Q ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of regorafenib in combination with cetuximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with Adverse Events as a measure of safety and tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax,md (Cmax after multiple dose) for regorafenib and cetuximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation with SUMD scale results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccination status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maximum amplitudes of the vibrating principal strain and maximum shear strain during vibration therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximum principal strain and maximum shear strain during habitual locomotor activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of Patients With Specific Protocol Defined Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Decisional conflict scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Wz% change in response to BD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Symptom score by e-Diary
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Spirometer - FEV1.0/FVC/PEF/MEF50
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hospitalization for myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hospitalization for cardiac revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hospitalization for ischemic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HPV virus load in cervical smears
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased physical activity (steps per day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ST2 expression in mitral valve tissue and papillary muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: progression of metabolic syndrome complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: estimation of metabolic syndrome deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in GAD65 Autoantibody Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in mIAA Autoantibody Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Microbiological Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Complete Response Rate (Cohort 1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmed Response Rate (Cohort 2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: renal function survival rate
Endpoint domain: Mortality/survival
Primary endpoint: days in the ICU
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Correspondence of pCLE Images to HRCT and Morphologic Data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of apnea without desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in ICIQ-OABqol HRQL Total Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Inter-Rectus Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunomodulation effect of Tranexamic Acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensitivity and specificity of the chewing gum test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biologic outcomes (HbA1c, lipid ratio, blood pressure, smoking status)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Plasma Omega-3 Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: maximal tolerated doses
Endpoint domain: Adverse events/effects
Primary endpoint: Completion rate of home-based program
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Modification in care through the nurse device
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Number of patients with postoperative ileus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Postoperative Atrial Fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Surgery healing complication
Endpoint domain: Adverse events/effects
Primary endpoint: Dissociation energy in EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of local and systemic vaccine-related clinical events
Endpoint domain: Adverse events/effects
Primary endpoint: Change from pre-immunisation baseline values in haematology parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Root mean square of the successive [R-R intervals] differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of dietary diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical Condition Determined by NIHSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Clinical Condition Determined by GCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: rSO2 measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EORTC Information-25 (EORTC-QLQ-INFO25)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Thickness of the average necrotic area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Flow Mediated Dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Progression on the Modified WHO Ordinal Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in daily hot flash frequency and severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Numeric Pain Rating Scale Average Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Offered and Screened for Distress
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants Offered an Appropriate Referral
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Subjective and objective results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean change in lean body mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: therapeutic success (passing ≥ 3 stools per week, with no loosening of stool)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Intra-articular hematoma assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: variation in sub-scores of specific baselines
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Self-reported Methamphetamine Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin surface moisture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: sequence of withdrawing life-sustaining treatment
Endpoint domain: Mortality/survival
Primary endpoint: Accuracy of the Simplified Screening Tool (SST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient preference for type of pegfilgrastim application
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peak Forced Expiratory Volume in One Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean Percentage of Enlite Sensor Values Within 20% Agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial lipid metabolism measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: partial pressure of carbon dioxide (PaCO2) decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Patients Who Maintain a Viral Load < 50 Copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time until T4/T1 ratio >0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lower limb muscle activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in carotenoid levels in the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in carotenoid levels in the eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearing of Anterior Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of epidural space identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Glucose Metabolism of the whole brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MRI PDFF correlation/agreement to UDFF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Zinc to copper ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Who Achieved > or Equal to 2 X 10(6) CD34+ Cells/kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: AUCτ,ss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cmax,ss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in aPTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes